Form 4: Arrowhead Pharmaceuticals Director Sells Shares Under 10b5-1 Plan

A director at Arrowhead Pharmaceuticals, Victoria Vakiener, sold 8,994 shares of common stock at an average price of $21.91, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Victoria Vakiener, a director at Arrowhead Pharmaceuticals, sold 8,994 shares of common stock on December 16, 2024.
• The sale was executed under a pre-arranged 10b5-1 trading plan.
• The shares were sold at a weighted average price of $21.91, with individual transaction prices ranging from $21.54 to $22.20.
• The transaction also included a partial disposition of Restricted Stock Units (RSUs) to cover tax withholding obligations.
• Following the transaction, Vakiener still beneficially owns 21,211 shares of common stock, including shares underlying RSUs.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged plan. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives and directors to use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among corporate insiders to manage their stock sales.
• The reported transaction is consistent with typical Form 4 filings for insider stock sales.
• The price range of $21.54 to $22.20 is within the expected trading range for the stock at the time of the transaction.

Stakeholder Impact

• The stock sale by a director may have a minor impact on shareholder sentiment, but it is unlikely to significantly affect the stock price given the pre-arranged nature of the sale.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, insider trading, Form 4, 10b5-1 plan, stock sale, director, Victoria Vakiener, equity securities, restricted stock units